Maxcyte (MXCT) Gross Margin (2020 - 2026)

Maxcyte (MXCT) has 7 years of Gross Margin data on file, last reported at 179.56% in Q1 2026.

• On a quarterly basis, Gross Margin rose 9397.0% year-over-year to 179.56% in Q1 2026; TTM through Mar 2026 was 172.5%, a 6943.0% increase from a year earlier, with the FY2025 full-year figure at 127.9%, down 1402.0% from the prior year.
• Gross Margin for Q1 2026 stood at 179.56%, up from 119.31% in the prior quarter.
• Over the last five years, Gross Margin for MXCT reached as high as 180.12% in Q2 2024 and fell as low as 119.31% in Q4 2025.
• Historically, Gross Margin has averaged 100.91% across 5 years, with a median of 88.34% in 2022.
• Across the five-year window, Gross Margin soared 9533 bps in 2024 and tumbled 22521 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 140.24% in 2022, then tumbled by 62 bps to 53.08% in 2023, then jumped by 99 bps to 105.9% in 2024, then plunged by 213 bps to 119.31% in 2025, then soared by 250 bps to 179.56% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 179.56% in Q1 2026, 119.31% in Q4 2025, and 76.63% in Q3 2025.